Promedior's novel therapeutics are designed to treat and prevent fibrotic
pathology by regulating the common cellular mechanisms that control the initiation and progression of fibrosis across a variety of tissues and organ systems.
Halo Therapeutics, LLC, is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for rare fibrotic
diseases like Duchenne muscular dystrophy.
Utilizing this novel approach, Promedior is initially developing drugs to address the most severe and difficult-to-treat fibrotic
and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, and diabetic retinopathy (eye); pulmonary fibrosis, scleroderma and COPD (lung); and acute and chronic nephropathy (kidney).
Based on this research and other clinical and preclinical studies, Promedior is developing a pipeline of drugs based upon recombinant forms of PTX-2/SAP for the treatment and prevention of fibrotic
and inflammatory diseases.
Their ear canals were occluded with fibrotic
tissue, which was induced after surgical operation in five subjects.
Moerae Matrix is a privately-held, clinical-stage company focused on the discovery and development of inhibitors of MAPKAP Kinase 2 to treat fibrotic
and inflammatory diseases.
In gold standard preclinical models of pulmonary fibrosis and other fibrotic
disorders, MMI-0100 has shown significant efficacy in both preventing scarring and fibrosis and treating established fibrosis.
In a new study, Salk scientists discovered that calcipotriol deactivates the switch governing the fibrotic
response in mouse liver cells, suggesting a potential new therapy for fibrotic
diseases in humans.
The otoscopic appearance of the left eardrum was similar to that seen in a case of tympanic membrane perforation, but the pathology was much more lateral and the eardrum could be visualized through the circumferential fibrotic
tissue involving the ear canal (figure 1).
Says Bonner, "Perhaps the most significant finding so far is that we defined the importance of two receptors--the platelet-derived growth factor receptor and the epidermal growth factor receptor--to the progression of lung fibrosis and showed that blocking these receptors with specific tyrosine kinase inhibitors reduced the fibrotic
effect of vanadium pentoxide in rats.
Her proven leadership will be critical to our success as we work to advance our proprietary pipeline in Pentraxin-2 therapeutics through clinical development in fibrotic
OTCQB: CRBP) (the "Company"), an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic
diseases, announced today that Yuval Cohen, Ph.